SCHEMBL24088906

SCHEMBL24088906

Cc1cnc2c(ncn2COCC[Si](C)(C)C)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.39
HSP90AA1 P07900 4/20 0.36
HSP90AB1 P08238 4/20 0.36
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
HPRT1 P00492 2/20 0.34
NR3C1 P04150 3/20 0.33
PNP P00491 2/20 0.33
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33
EDNRA P25101 1/20 0.33
HTR2A P28223 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
HBB P68871 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ENPP1 P22413 2/20 0.32
NT5E P21589 1/20 0.32
HSP90B1 P14625 1/20 0.32
TRAP1 Q12931 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14697559 0.86 DGAT1 (0.38) DGAT1BRD4CREBBPHPRT1NR3C1
SCHEMBL15544850 0.83 BRD4 (0.37) DGAT1BRD4CREBBPHPRT1NR3C1
SCHEMBL15560648 0.83 NR3C1 (0.33) DGAT1BRD4CREBBPHPRT1NR3C1
SCHEMBL14697499 0.82 NR3C1 (0.45) HPRT1NR3C1TSHR
SCHEMBL26640909 0.79 DGAT1 (0.41) DGAT1BRD4CREBBPHPRT1PNP
SCHEMBL357273 0.78 FDPS (0.45) ENPP1NT5E
SCHEMBL31340868 0.78 FDPS (0.45) ENPP1NT5E
SCHEMBL16977995 0.78 DGAT1 (0.38) DGAT1HSP90AA1BRD4CREBBP
SCHEMBL18975732 0.77 HPRT1 (0.35) DGAT1BRD4CREBBPHPRT1PNP
SCHEMBL30907555 0.77 BRD4 (0.35) DGAT1BRD4CREBBPHPRT1PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840534-B2 Substituted tricyclic compounds as FGFR inhibitors INCYTE CORPORATION (US) 2023-12-12 US disclosed
US-20210380587-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS INCYTE HOLDINGS CORPORATION 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840534-B2 Substituted tricyclic compounds as FGFR inhibitors FGFR3, FGFR1, FGFR2 DGAT1 1357/4885HSP90AA1 1446/4885HSP90AB1 941/4885
US-20210380587-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 DGAT1 1357/4885HSP90AA1 1446/4885HSP90AB1 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.